1 / 26

Going Beyond EXTREME in Head and Neck Cancer

Going Beyond EXTREME in Head and Neck Cancer. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Introduction. KEYNOTE-012 Long-Term Follow-Up. CheckMate-141 Phase 3 Trial.

stahr
Download Presentation

Going Beyond EXTREME in Head and Neck Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Going Beyond EXTREME in Head and Neck Cancer

  2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

  3. Introduction

  4. KEYNOTE-012Long-Term Follow-Up

  5. CheckMate-141Phase 3 Trial

  6. CheckMate-141Results

  7. KEYNOTE-040Phase 3 Trial

  8. Notes on KEYNOTE-040

  9. Further Notes on Checkpoint Inhibition in the Second Line

  10. PD-L1 as a Biomarker

  11. Use of Biomarkers

  12. KEYNOTE-048 First-Line TrialTrial Design

  13. Use of CPS in KEYNOTE-048

  14. KEYNOTE-048OS Results of Pembrolizumab Monotherapy vs EXTREME

  15. KEYNOTE-048Results of Pembrolizumab Monotherapy vs EXTREME (cont)

  16. KEYNOTE-048OS Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population

  17. KEYNOTE-048Results of Pembrolizumab + Chemotherapy vs EXTREME, Total Population (cont)

  18. Notes on KEYNOTE-048

  19. Comparison With Chemoimmunotherapy in NSCLC

  20. Further Notes on KEYNOTE-048

  21. Study Implications

  22. Ongoing Phase 3, First-Line Trials

  23. Thoughts About the Future of Immunotherapy in SCCHN

  24. Abbreviations

  25. Abbreviations (cont)

More Related